Insulet Reports Third Quarter 2019 Revenue of $192 Million, an Increase of 27% Year-Over-Year
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Insulet (PODD) Misses Q3 EPS by 2c, Revenues Beat; Offers FY19 Revenue Guidance Above Consensus
November 5, 2019 4:33 PM ESTInsulet (NASDAQ: PODD) reported Q3 EPS of $0.01, $0.02 worse than the analyst estimate of $0.03. Revenue for the quarter came in at $192.1 million versus the consensus estimate of $179.49 million.
Third Quarter Financial Highlights:
Third quarter revenue of $192.1 million, up 27%, compared to revenue of $151.1 million in the prior year, exceeds guidance of $174 to $181 millionGlobal Omnipod revenue of $177.2 million, an increase of 34%U.S. Omnipod revenue of $109.5 million, an increase of 34%International Omnipod revenue of $67.7 million, an increase of 35%Drug Delivery revenue of $14.9 million, a decrease of 21%Gross margin of... More